Development plans of NY-500, an AI-Optimized PD-1 x VEGF Bifunctional Antibody, announced in multiple oncology indications January 15, 2025
RYBREVANT® (amivantamab-vmjw) + LAZCLUZE™ (lazertinib) shows statistically significant and clinically meaningful improvement in OS versus osimertinib January 15, 2025
FDA clears IND for Ph 1/2 clinical trial of REC-4539 in SCLC and MHRA clears IND for Ph 1 clinical trial of REC-3565 for B-cell malignancies January 15, 2025
European Commission approves RYBREVANT (amivantamab) + LAZCLUZE (lazertinib) for the 1L treatment of patients with EGFR-mutated advanced NSCLC January 7, 2025
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849 Targeting SCLC and NET Solid Tumors December 31, 2024
US FDA Accepts for Priority Review NDA for Taletrectinib for the Treatment of Advanced ROS1+ve NSCLC December 31, 2024
Datopotamab Deruxtecan Application in the EU for Patients with Advanced non-sqNSCLC Voluntarily Withdrawn December 31, 2024
FDA issues CRL for BLA for fixed combination of amivantamab and human hyaluronidase for SC amivantamab in patients with NSCLC with EGFR mutations December 26, 2024
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for 2L Treatment of ES-SCLC December 26, 2024
Initial clinical results from ongoing KYANITE-1 study of inhaled KB707 in patients with solid tumors of the lung announced December 25, 2024
Tagrisso approved in the EU for patients with unresectable EGFR-mutated lung cancer December 25, 2024
Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V) presented December 18, 2024
Neoadjuvant KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemo, Then Continued as Monotherapy as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC December 17, 2024
Ph 3 POD1UM-304 trial of Retifanlimab (Zynyz®) + Chemo met primary endpoint of OS and all secondary endpoints in patients with 1L metastatic NSCLC December 10, 2024
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated NSCLC December 10, 2024
First Patient Enrolled in Taiwan for Ph 2 HARMONIC™ Trial of LP-300 in Never-Smoker NSCLC Patients December 10, 2024
Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFRMutated NSCLC in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis December 10, 2024
FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous NSCLC With EGFR Mutations December 10, 2024
